Boost COVID-19 vaccine R&D with rapid serology tests and minimal sample and reagent consumption (Part III)

Apr 5, 2021 1:30:00 PM

The COVID-19 pandemic has necessitated the need to 

COVID-19 vaccine R&D rapid serology tests (Part III)

generate serology data on the levels of IgM and IgG directed against the RBD of SARS-CoV-2 to help in identifying individuals with neutralizing antibodies and drive the development of therapeutics and vaccines. A number of plate-based immunoassay platforms are being employed for serology testing but there are often issues with high reagent and sample consumption, plus the limitations of laborious manual workflows and long turnaround times. Open platforms are needed that enable data to be rapidly generated using small amounts of reagent and sample, preferably over a broad analytical range to minimize the need for repeat analysis. This is now possible in an open automated platform that uses minimal amounts of precious reagent and sample. 


An open platform to enable rapid data generation in a dynamic R&D environment

A review article from 2019 that, in a way, foresaw the COVID-19 pandemic by less than a year, pointed out, “In the case of emerging infectious diseases, it can be difficult to predict what assays will be most useful or informative or will perhaps even provide an immune correlate of protection for a vaccine in early development” (1). Typical methods used in vaccine R&D include enzyme-linked immunosorbent assays (ELISA), virus neutralization or bactericidal immunoassays, and ELISpot.

 

The assay toolbox evolves over time from early vaccine development to increase throughput, reduce sample volumes, and automation to enable increased throughput for late-stage clinical trials.


One platform that has emerged as an established and valuable alternative to ELISA is the Gyrolab® platform, which offers a number of advantages when running established assays, such as for SARS-CoV-2 antibodies, and also when transferring assays, or developing new ones (Table 1).

 


Table 1. Comparison of Gyrolab immunoassay performance to ELISA


Gyrolab SARS-CoV-2 Total Antibody Assay

In response to the COVID-19 pandemic, Gyros Protein Technologies has developed a three-step bridging serologic immunoassay test using commercially available reagents to be run on the open Gyrolab platform. The assay has a broad analytical range for qualitative detection of total antibodies generated against the spike protein (RBD) of SARS-CoV-2 in human serum samples.


The qualitative, Gyrolab SARS-CoV-2 Total Antibody Assay* can be used to detect antibodies over a broad range of concentrations, from 40 ng/mL to 200 µg/mL. Adding unlabeled RBD completely inhibited the response from positive controls, confirming the specificity of the assay, and the responses from 50 pre-pandemic serum samples were equivalent to negative controls. The open Gyrolab platform also enables this SARS-CoV-2 RBD immunoassay to be readily complemented with immunoassays directed to other targets.


Find out more by downloading the White Paper: One-hour, microfluidic SARS-CoV-2 antibody immunoassay using Sino Biological reagents and Gyrolab® immunoassay platform.

 

*Note that this assay has been developed for research use only and is not intended for diagnostic use.

References

  1. Emerging infectious disease laboratory and diagnostic preparedness to accelerate vaccine development. Roberts, C. Human vaccines & immunotherapeutics 2019, 15 (10) 2258–2263 https://doi.org/10.1080/21645515.2019.1634992

Topics: Vaccine